Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2 -mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phas...
Saved in:
| Published in: | Nature communications Vol. 14; no. 1; pp. 630 - 12 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
06.02.2023
Nature Publishing Group Nature Portfolio |
| Subjects: | |
| ISSN: | 2041-1723, 2041-1723 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!